Inhaled Nitric Oxide Delivery Systems Industry

According to a new report by Grand View Research, Inc., the global market for inhaled nitric oxide (INO) delivery systems is projected to reach a valuation of USD 434.2 million by the year 2028. The market is expected to expand at a compound annual growth rate (CAGR) of 6.9% during the forecast period. Several factors are contributing to this growth, including the rising incidence of respiratory failure in neonates, increasing levels of environmental pollution that lead to lung diseases in adults, and the growing need for treatments that offer rapid therapeutic responses with minimal complications. These factors are collectively accelerating the adoption of inhaled nitric oxide therapy across a range of patient populations.

Additionally, the market is being positively influenced by the presence of numerous small-scale manufacturers who contribute to increased accessibility and competition, as well as by research initiatives led by major industry players aimed at establishing the efficacy of inhaled nitric oxide as a potential treatment for complications arising from the SARS-CoV-2 virus. These ongoing studies and collaborations are expected to further strengthen the market during the forecast period.

Inhaled nitric oxide therapy offers several notable advantages over other medication delivery methods. These include a safe and effective treatment profile, rapid onset of action, minimal toxicity, high drug concentration delivered directly to the target organ, reduced risk of systemic side effects, and lower overall dosage requirements. These benefits collectively enhance the attractiveness and clinical value of INO therapy, thereby promoting its widespread adoption.

Leading companies in the market, such as Mallinckrodt Pharmaceuticals, are actively supporting the advancement of INO therapy through investments and funding for clinical trials, particularly those focused on evaluating its effectiveness in treating complications associated with COVID-19. Such strategic initiatives are expected to contribute significantly to market growth over the projected period.

Curious about the Inhaled Nitric Oxide Delivery Systems Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Inhaled Nitric Oxide Delivery Systems Market Segments Highlights:

  • The pediatric type segment accounted for the largest revenue share in 2023 due to the rising usage of INO therapy on account of its efficacy and reduced complications
  • The Hypoxic Respiratory Failure (HRF) application segment held the largest revenue share in 2023
  • Hospitals was the largest revenue-generating segment in 2023 owing to the presence of funds and well-established infrastructure in this end-user setting
  • Asia Pacific was the largest regional market in 2023 due to the growing pediatric population, rise in the cases of respiratory diseases, and presence of local manufacturers of disposables

Inhaled Nitric Oxide Delivery Systems Market Report Segmentation

Grand View Research has segmented the global inhaled nitric oxide delivery systems market report based on type, application, product, end use and region:

Inhaled Nitric Oxide Delivery Systems Type Outlook (Revenue, USD Million, 2016 - 2028)

  • Pediatric
  • Adult

Inhaled Nitric Oxide Delivery Systems Application Outlook (Revenue, USD Million, 2016 - 2028)

  • Hypoxic Respiratory Failure (HRF)
  • Acute Hypoxemic Respiratory Failure (AHRF)
  • Others

Inhaled Nitric Oxide Delivery Systems Product Outlook (Revenue, USD Million, 2016 - 2028)

  • Disposables
  • System

Inhaled Nitric Oxide Delivery Systems End-user Outlook (Revenue, USD Million, 2016 - 2028)

  • Hospitals
  • Ambulatory Centers
  • Clinics

Inhaled Nitric Oxide Delivery Systems Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Key Inhaled Nitric Oxide Delivery Systems Company Insights

  • Mallinckrodt Pharmaceuticals
  • Getinge AB
  • VERO Biotech
  • Linde plc
  • Beyond Air, Inc.
  • SLE Ltd.
  • Bellerophon Therapeutics
  • Air Liquide Healthcare
  • Circassia Pharmaceuticals
  • International Biomedical

Order a free sample PDF of the Inhaled Nitric Oxide Delivery Systems Market Intelligence Study, published by Grand View Research.